NEW YORK (GenomeWeb) – Abbott announced today that it has received CE marking for its Alinity m molecular diagnostics system and assays, which are now available in countries that recognize the designation.
The firm said that its molecular system will help clinicians who are struggling to keep up with demand for infectious disease testing.
The MDx platform offers a number of initial assays, including virology testing for human immunodeficiency virus type 1, hepatitis B virus, and hepatitis C virus; sexual health-related testing for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, or a CT/NG/TV/MG panel; and high-risk human papillomavirus testing.
Abbott said that the molecular system and assays provide flexibility for laboratory staff and faster testing results for clinicians and patients, and that it may reduce the lab equipment footprint from between four and six instruments to one. As a result, the system decreases space requirements and hours spent learning and maintaining different instruments, the firm said.
The Alinity m is not available in the US for diagnostic use.
The molecular diagnostic platform is part of a series of next-generation systems and assays from Abbott that also includes clinical chemistry, immunoassay, and hematology testing, and blood and plasma screening.